Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity.

Area of Science:

• Virology
• Biotechnology
• Medical Countermeasures

Background:

• Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) poses a significant global health threat.
• Viral entry into host cells is a critical step in infection.
• Developing effective countermeasures against rapidly mutating viruses like SARS-CoV-2 is essential.

Purpose of the Study:

• To investigate cellular nanosponges as a novel medical countermeasure against SARS-CoV-2.
• To determine if nanosponges derived from human lung epithelial type II cells or macrophages can neutralize the virus.
• To assess the nanosponge platform's efficacy against viral mutations and different species.

Main Methods:

• Fabrication of cellular nanosponges using plasma membranes from human lung epithelial type II cells and human macrophages.
• Characterization of nanosponges for display of protein receptors utilized by SARS-CoV-2 for cellular entry.
• In vitro incubation of SARS-CoV-2 with nanosponges.
• Assessment of viral infectivity post-incubation.

Main Results:

• Cellular nanosponges effectively neutralized SARS-CoV-2 in vitro.
• Nanosponges displayed key SARS-CoV-2 cellular entry receptors.
• The nanosponge platform demonstrated broad efficacy, remaining effective against viral mutations and potentially other viral species.

Conclusions:

• Cellular nanosponges represent a promising and versatile medical countermeasure for SARS-CoV-2.
• The nanosponge platform's ability to target host cell receptors offers a mutation-agnostic approach to viral neutralization.
• This technology holds potential for combating current and future viral threats.